Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Bitcoin to Skyrocket: Multi‑Year Channel Breakout?

Bitcoin to Skyrocket: Multi‑Year Channel Breakout?

BitgetBitget2025/07/01 11:08
By:Bitget
  • Bitcoin nearing breakout from long-term channel
  • Intermediate target set at $140 k
  • Year-end goal remains $200 k amid bullish momentum

Beyond the Ascending Wedge Myth

Despite some calling it an ascending wedge—a classic bearish reversal pattern—the current Bitcoin price structure doesn’t fit that mold. Instead, analysts identify a multi-year channel—a broad, upward-sloping range that Bitcoin has respected since around 2020. This structure hints at accumulated gains rather than exhaustion.

Channels differ from wedges: they reflect sustained trend stability, not reversal buildup. Bitcoin has been testing the upper boundary of this channel, acting as resistance for months. Momentum appears to be building for a breakout.

Are We on the Cusp of a Rocket Move?

Should Bitcoin breach the channel’s upper resistance decisively—ideally on strong volume—a significant rally could follow. Technical analysts suggest that the next leg might be explosive, fueled by renewed investor enthusiasm and institutional capital flow.

The intermediate target? Around $140,000—a projected extension matching previous channels and measured moves. If that zone holds and crypto market sentiment stays hot, the year-end target could reach $200,000—a bold forecast based on continued trend strength and broader adoption.

This formation is not an ascending wedge.

Bitcoin is about to break out of a multi-year channel.

The next leg will be explosive.

Intermediate target: 140k.
Year-end target: 200k. pic.twitter.com/NkftUJUGeh

— Stockmoney Lizards (@StockmoneyL) June 30, 2025

What Could Fuel This Surge?

Key drivers potentially supporting the breakout include:

  • Institutional Inflows: Products like Bitcoin ETFs, staking vehicles, and asset manager interest may bring fresh capital.
  • Macro Conditions: Economic policies encouraging yield-seeking assets, alongside mounting inflation concerns, could elevate Bitcoin as a hedge.
  • Network Effects: Continued growth in Bitcoin use cases—like Lightning Network adoption and on‑chain activity—reinforces its utility and narrative.

Still, bullish forecasts rest on key conditions: maintaining buying volume, avoiding sharp macroeconomic shocks, and sidestepping regulatory setbacks.

Read Also:

  • Polkadot Hits $146M Volume, Tezos Rises, and With Qubetics Live on MEXC and LBank, Is it the Best Crypto Under $1 to Watch?
  • Bitcoin to Skyrocket: Multi‑Year Channel Breakout?
  • SOL Rockets to $160 as U.S. Debuts First Solana Staked ETF
  • Trump‑Backed American Bitcoin Raises $215M to Buy BTC
  • Hacker Sinks $6.9M in Crypto Trading Blunder
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stock IPO Preview | From Losses to Net Profit of 5.46 Million: The "Three-Dimensional" Platform Business Strategy with a Taste for Golf

Crossing the break-even line, the growth inflection point has arrived.

智通财经•2026/11/11 03:22

Core CPI Exceeds Expectations Again, Fed Hawks Loud! 2027 FOMC Voting Member Directly Calls Inflation Hot

Austan Goolsbee, President of the Chicago Federal Reserve, stated that officials must address the issue of high inflation, and described the October consumer price report as worrisome.

智通财经•2026/11/11 03:06

Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality

The FDA requires all GLP-1 drugs to include a warning about the rare eye disease NAION. Novo Nordisk and Eli Lilly deny any causality, while Citi states that the impact on adoption is limited.

智通财经•2026/11/11 02:56
Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality